NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome‐dependent degradation of ISGylated p53

Author:

Ren Yonggang123ORCID,Yang Jing1,Ding Zhiran1,Zheng Menghua1,Qiu Lu4,Tang Aifa5ORCID,Huang Dandan1

Affiliation:

1. Institute of Basic Medicine and Forensic Medicine North Sichuan Medical College Nanchong China

2. Research Center of Clinical Medical Sciences Affiliated Hospital of North Sichuan Medical College Nanchong China

3. Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Institute of Translational Medicine, Shenzhen Second People's Hospital The First Affiliated Hospital of Shenzhen University Shenzhen China

4. School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat‐Sen University Shenzhen China

5. Shenzhen Luohu Hospital Group The Third Affiliated Hospital of Shenzhen University Shenzhen China

Abstract

AbstractNuclear factor erythroid 2‐like 3 (NFE2L3) is a member of the cap ‘n’ collar basic‐region leucine zipper (CNC‐bZIP) transcription factor family that plays a vital role in modulating oxidation–reduction steady‐state and proteolysis. Accumulating evidence suggests that NFE2L3 participates in cancer development; however, little is known about the mechanism by which NFE2L3 regulates hepatocellular carcinoma (HCC) cell growth. Here, we confirmed that NFE2L3 promotes HCC cell proliferation by acting as a transcription factor, which directly induces the expression of proteasome and interferon‐stimulated gene 15 (ISG15) to enhance the proteasome‐dependent degradation of ISGylated p53. Post‐translational ISGylation abated the stability of p53 and facilitated HCC cell growth. In summary, we uncovered the pivotal role of NFE2L3 in promoting HCC cell proliferation during proteostasis. This finding may provide a new target for the clinical treatment of HCC.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Sichuan Province

Shenzhen Science and Technology Innovation Commission

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3